SI2282778T1 - Novi terapevtski pristopi za zdravljenje Alzheimerjeve bolezni in sorodnih motenj z modulacijo angiogenezo - Google Patents
Novi terapevtski pristopi za zdravljenje Alzheimerjeve bolezni in sorodnih motenj z modulacijo angiogenezoInfo
- Publication number
- SI2282778T1 SI2282778T1 SI200931641A SI200931641A SI2282778T1 SI 2282778 T1 SI2282778 T1 SI 2282778T1 SI 200931641 A SI200931641 A SI 200931641A SI 200931641 A SI200931641 A SI 200931641A SI 2282778 T1 SI2282778 T1 SI 2282778T1
- Authority
- SI
- Slovenia
- Prior art keywords
- angiogenesis
- modulation
- related disorders
- alzheimer disease
- new therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4858308P | 2008-04-29 | 2008-04-29 | |
| PCT/EP2009/055205 WO2009133141A2 (en) | 2008-04-29 | 2009-04-29 | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis |
| EP09738185.9A EP2282778B1 (en) | 2008-04-29 | 2009-04-29 | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2282778T1 true SI2282778T1 (sl) | 2017-07-31 |
Family
ID=41222690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200931641A SI2282778T1 (sl) | 2008-04-29 | 2009-04-29 | Novi terapevtski pristopi za zdravljenje Alzheimerjeve bolezni in sorodnih motenj z modulacijo angiogenezo |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11291670B2 (sl) |
| EP (1) | EP2282778B1 (sl) |
| JP (1) | JP5721230B2 (sl) |
| KR (1) | KR101660401B1 (sl) |
| CN (1) | CN102065898B (sl) |
| AU (1) | AU2009242126B2 (sl) |
| BR (1) | BRPI0911520A2 (sl) |
| CA (1) | CA2722453C (sl) |
| CY (1) | CY1118956T1 (sl) |
| DK (1) | DK2282778T3 (sl) |
| EA (1) | EA021731B1 (sl) |
| ES (1) | ES2622504T3 (sl) |
| HR (1) | HRP20170531T1 (sl) |
| HU (1) | HUE033726T2 (sl) |
| IL (1) | IL208982B (sl) |
| LT (1) | LT2282778T (sl) |
| MX (1) | MX2010011881A (sl) |
| NZ (1) | NZ589307A (sl) |
| PL (1) | PL2282778T3 (sl) |
| PT (1) | PT2282778T (sl) |
| SI (1) | SI2282778T1 (sl) |
| WO (1) | WO2009133141A2 (sl) |
| ZA (1) | ZA201008037B (sl) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| CN102065858B (zh) * | 2008-04-29 | 2014-07-02 | 法奈科斯公司 | 使用唑尼沙胺和阿坎酸治疗阿尔茨海默病和相关病症的组合组合物 |
| EP2135607A1 (en) | 2008-06-18 | 2009-12-23 | Pharnext | Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders |
| HUE037938T2 (hu) | 2008-11-19 | 2018-09-28 | Forum Pharmaceuticals Inc | Skizofrénia negatív tüneteinek kezelése (R)-7-klór-N-(kinuklidin-3-il)benzo[b]tiofén-2-karboxamiddal és ennek gyógyszerészetileg elfogadható sójával |
| RU2011150248A (ru) * | 2009-05-11 | 2013-06-20 | Энвиво Фармасьютикалз, Инк. | Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы |
| US9387206B2 (en) | 2009-11-03 | 2016-07-12 | Pharnext | Therapeutic approaches for treating Alzheimer's disease |
| EP2322163A1 (en) * | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| PT3029039T (pt) | 2010-05-17 | 2017-11-28 | Forum Pharmaceuticals Inc | Formulações farmacêuticas que compreendem formas cristalinas de cloridrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida mono-hidratado |
| CN103153295A (zh) | 2010-08-24 | 2013-06-12 | 艾格埃克斯制药有限公司 | 来氟米特和丙二腈酰胺类似物的新用途 |
| DE102010062810B4 (de) * | 2010-09-07 | 2014-03-13 | Immungenetics Ag | 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien |
| EP2673363B1 (en) * | 2011-02-11 | 2017-08-23 | The Rockefeller University | Treatment of angiogenesis disorders |
| UA115968C2 (uk) * | 2011-03-01 | 2018-01-25 | Фарнекст | Нові композиції для лікування неврологічних захворювань |
| EP2560631B1 (en) | 2011-03-01 | 2014-01-15 | Pharnext | Baclofen and acamprosate based therapy of neurogical disorders |
| US9248111B2 (en) | 2011-03-01 | 2016-02-02 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| JP6430445B2 (ja) * | 2011-03-01 | 2018-11-28 | ファーネクストＰｈａｒｎｅｘｔ | バクロフェンおよびアカンプロセートに基づく神経疾患の治療 |
| US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
| US9867837B2 (en) | 2011-03-01 | 2018-01-16 | Pharnext | Compositions for treating neurological disorders |
| US10010515B2 (en) | 2011-03-01 | 2018-07-03 | Pharnext | Therapeutic approaches for treating Parkinson's disease |
| EP2705842A1 (en) | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| US9931326B2 (en) | 2011-03-29 | 2018-04-03 | Pharnext | Composition comprising torasemide and baclofen for treating neurological disorders |
| EP3235498A1 (en) * | 2012-03-01 | 2017-10-25 | Pharnext | New compositions for treating amyotrophic lateral sclerosis |
| AU2013224959B2 (en) * | 2012-03-01 | 2017-12-07 | Pharnext | New compositions for treating amyotrophic lateral sclerosis |
| CA2872005A1 (en) | 2012-05-08 | 2013-11-14 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
| US8962020B2 (en) * | 2012-07-26 | 2015-02-24 | Glycadia Inc. | Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid |
| EP2705841A1 (en) | 2012-09-05 | 2014-03-12 | Pharnext | Combinations of nootropic agents for treating cognitive dysfunctions |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| KR101579008B1 (ko) * | 2013-09-25 | 2015-12-22 | 경북대학교 산학협력단 | ERR-γ 저해제를 포함하는, 망막병증의 예방 또는 치료용 약학적 조성물 및 이의 용도 |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| WO2015121218A1 (en) | 2014-02-11 | 2015-08-20 | Pharnext | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders |
| CN104928353A (zh) * | 2014-03-19 | 2015-09-23 | 上海吉凯基因化学技术有限公司 | 人dgkz基因的用途及其相关药物 |
| US20180028520A1 (en) * | 2014-09-30 | 2018-02-01 | The Trustees Of Columbia University In The City Of New York | Methods and pharmaceutical compositions for treatment of amyotrophic lateral sclerosis |
| WO2016201086A1 (en) * | 2015-06-12 | 2016-12-15 | Rush University Medical Center | Compositions and methods for stimulating adam10-mediated nonamyloidogenic proteolysis of amyloid precursor protein |
| AU2017216288B2 (en) * | 2016-02-05 | 2022-06-02 | Pharnext | Novel combinatorial therapies of neurological disorders |
| US11033524B2 (en) | 2016-11-23 | 2021-06-15 | Ramot At Tel-Aviv University Ltd. | Methods and compositions for treating disorders associated with cortico-hippocampal hyperactivity |
| JP7065880B2 (ja) | 2017-04-24 | 2022-05-12 | ファーネクスト | アルツハイマー病のイダロピルジン系組合せ療法 |
| US11439608B2 (en) | 2017-09-25 | 2022-09-13 | Qun Lu | Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease |
| WO2019094434A1 (en) * | 2017-11-07 | 2019-05-16 | The Regents Of The University Of Michigan | Therapeutic combination for treatment of cerebellar ataxia |
| CN111084768A (zh) * | 2018-10-24 | 2020-05-01 | 中国科学院昆明动物研究所 | 吉非罗齐及其衍生物用于治疗和/或预防神经退行性疾病的用途 |
| JPWO2020111171A1 (ja) * | 2018-11-29 | 2021-11-25 | 雪印メグミルク株式会社 | 血管新生促進用組成物 |
| CN110806488B (zh) * | 2019-12-06 | 2020-09-25 | 南京医科大学 | Drd5及其激动剂在制备治疗炎症性疾病的药物中的应用 |
| WO2023059867A1 (en) * | 2021-10-08 | 2023-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds for treating or preventing alzheimer's disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH072688A (ja) * | 1991-06-11 | 1995-01-06 | Rikomu:Kk | 腸内有毒腐敗産物抑制剤 |
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| ES2124800T3 (es) * | 1993-01-08 | 1999-02-16 | Hoechst Ag | Empleo de leflunomida para la inhibicion de interleuquina 1 beta. |
| AUPS017702A0 (en) * | 2002-01-25 | 2002-02-14 | Atopic Pty Ltd | Methods and compositions for the treatment of asthma and related disorders |
-
2009
- 2009-04-29 SI SI200931641A patent/SI2282778T1/sl unknown
- 2009-04-29 CA CA2722453A patent/CA2722453C/en active Active
- 2009-04-29 KR KR1020107026061A patent/KR101660401B1/ko active IP Right Grant
- 2009-04-29 JP JP2011506707A patent/JP5721230B2/ja active Active
- 2009-04-29 MX MX2010011881A patent/MX2010011881A/es active IP Right Grant
- 2009-04-29 ES ES09738185.9T patent/ES2622504T3/es active Active
- 2009-04-29 CN CN200980122773.4A patent/CN102065898B/zh active Active
- 2009-04-29 PT PT97381859T patent/PT2282778T/pt unknown
- 2009-04-29 EA EA201071244A patent/EA021731B1/ru not_active IP Right Cessation
- 2009-04-29 PL PL09738185T patent/PL2282778T3/pl unknown
- 2009-04-29 HU HUE09738185A patent/HUE033726T2/en unknown
- 2009-04-29 NZ NZ589307A patent/NZ589307A/en not_active IP Right Cessation
- 2009-04-29 BR BRPI0911520A patent/BRPI0911520A2/pt not_active Application Discontinuation
- 2009-04-29 EP EP09738185.9A patent/EP2282778B1/en active Active
- 2009-04-29 AU AU2009242126A patent/AU2009242126B2/en active Active
- 2009-04-29 WO PCT/EP2009/055205 patent/WO2009133141A2/en active Application Filing
- 2009-04-29 LT LTEP09738185.9T patent/LT2282778T/lt unknown
- 2009-04-29 DK DK09738185.9T patent/DK2282778T3/en active
-
2010
- 2010-10-28 IL IL208982A patent/IL208982B/en active IP Right Grant
- 2010-10-29 US US12/915,709 patent/US11291670B2/en active Active
- 2010-11-10 ZA ZA2010/08037A patent/ZA201008037B/en unknown
-
2017
- 2017-04-03 HR HRP20170531TT patent/HRP20170531T1/hr unknown
- 2017-04-13 CY CY20171100439T patent/CY1118956T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009133141A3 (en) | 2009-12-30 |
| PL2282778T3 (pl) | 2017-08-31 |
| CN102065898B (zh) | 2015-08-26 |
| BRPI0911520A2 (pt) | 2017-06-13 |
| DK2282778T3 (en) | 2017-05-01 |
| EP2282778A2 (en) | 2011-02-16 |
| MX2010011881A (es) | 2011-07-01 |
| KR20110010734A (ko) | 2011-02-07 |
| CA2722453C (en) | 2018-03-20 |
| US20120058992A1 (en) | 2012-03-08 |
| LT2282778T (lt) | 2017-06-26 |
| NZ589307A (en) | 2012-04-27 |
| CA2722453A1 (en) | 2009-11-05 |
| EA021731B1 (ru) | 2015-08-31 |
| KR101660401B1 (ko) | 2016-09-27 |
| JP2011518864A (ja) | 2011-06-30 |
| WO2009133141A2 (en) | 2009-11-05 |
| PT2282778T (pt) | 2017-04-27 |
| CY1118956T1 (el) | 2018-01-10 |
| EA201071244A1 (ru) | 2011-06-30 |
| AU2009242126A1 (en) | 2009-11-05 |
| CN102065898A (zh) | 2011-05-18 |
| HRP20170531T1 (hr) | 2017-06-16 |
| EP2282778B1 (en) | 2017-03-08 |
| ZA201008037B (en) | 2011-08-31 |
| ES2622504T3 (es) | 2017-07-06 |
| IL208982A0 (en) | 2011-01-31 |
| AU2009242126B2 (en) | 2014-03-27 |
| HUE033726T2 (en) | 2017-12-28 |
| US11291670B2 (en) | 2022-04-05 |
| JP5721230B2 (ja) | 2015-05-20 |
| IL208982B (en) | 2018-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201008037B (en) | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis | |
| ZA201008039B (en) | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response | |
| HRP20182147T8 (hr) | Novi terapijski pristupi za liječenje cmt-a i srodnih poremećaja | |
| IL219412A0 (en) | New therapeutic approaches for treating alzheimer disease | |
| HK1158172A1 (en) | Compounds for treating ophthalmic diseases and disorders | |
| ZA200905962B (en) | Combination therapy for treatment of immune disorders | |
| GB0703909D0 (en) | Treatment of anxiety disorders | |
| IL218321A0 (en) | Therapeutic agent for mood disorders | |
| GB0915259D0 (en) | Sulphur-linked compounds for treating ophthalmic diseases and disorders | |
| HRP20171418T1 (hr) | Terapeutsko sredstvo za poremećaje anksioznosti | |
| SI2278962T1 (sl) | Postopki za zdravljenje dermatoloških motenj | |
| IL210558A0 (en) | Treatment of anxiety disorders | |
| ZA201100325B (en) | Treatment of anxiety disorders |